Treatment of HCV infection in patients with steatotic liver disease

Treatment of HCV infection in patients with steatotic liver disease

Saved in:

Bibliographic Details
Main Authors:	Robert Flisiak, Dorota Zarębska-Michaluk, Krystyna Dobrowolska, Justyna Janocha-Litwin, Dorota Dybowska, Marek Sitko, Łukasz Socha, Beata Lorenc, Jakub Klapaczyński, Jakub Brodowski
Format:	Article
Language:	English
Published:	Termedia Publishing House 2024-07-01
Series:	Clinical & Experimental Hepatology
Subjects:	treatment liver hcv steatotic liver disease
Online Access:	https://www.termedia.pl/Treatment-of-HCV-infection-in-patients-with-steatotic-liver-disease,80,54506,1,1.html
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Liver cancer risk and changes in lifestyle habits after successful hepatitis C virus therapy post-DAA HCV therapy: lifestyle changes and liver cancer risk
by: Núria Granel, et al.
Published: (2025-02-01)

Uric acid as a potential marker of cardiometabolic risk in children and adolescents with metabolic dysfunction associated steatotic liver disease
by: Katarzyna Zdanowicz, et al.
Published: (2024-09-01)

Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation
by: K. L. Raikhelson, et al.
Published: (2024-05-01)

Metabolic associated steatotic liver disease misses fewer high-risk patients than metabolic associated fatty liver disease
by: Yu-Ming Cheng, et al.
Published: (2024-12-01)

PBMCs gene expression predicts liver fibrosis regression after successful HCV therapy in HIV/HCV-coinfected patients
by: Ana Virseda-Berdices, et al.
Published: (2025-01-01)

Effectiveness of glecaprevir/pibrentasvir in HIV/HCV-coinfected patients treated with bictegravir/emtricitabine/tenofovir alafenamide
by: Aleksandra Berkan-Kawińska, et al.
Published: (2024-07-01)

Lachnospiraceae-bacterium alleviates ischemia-reperfusion injury in steatotic donor liver by inhibiting ferroptosis via the Foxo3-Alox15 signaling pathway
by: Shenghe Deng, et al.
Published: (2025-12-01)

Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma
by: Melchor Alpízar Salazar, et al.
Published: (2025-01-01)

Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021
by: Gong Feng, et al.
Published: (2025-03-01)

Changes in DNA methylation profile in liver tissue during progression of HCV-induced fibrosis to hepatocellular carcinoma
by: I. A. Goncharova, et al.
Published: (2023-03-01)

The impact of fasting on cardiovascular risk control in patients with metabolic dysfunction-associated steatotic liver disease
by: Anna E. Płatek, et al.
Published: (2023-09-01)

Effect of a Ketogenic Diet on Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Progression: A Randomized Controlled Trial
by: Sakkarin Chirapongsathorn, et al.
Published: (2025-01-01)

Liver macrophage activation: Relation with hepatic histopathological changes in patients with metabolic associated steatotic liver disease
by: Doaa H. Hegazy, et al.
Published: (2024-06-01)

Prevalence of HDV, HCV, and HIV Infection in the Population of Patients Infected with HBV in a Romanian Cohort
by: Antoanela Curici, et al.
Published: (2025-01-01)

From gut to liver: Exploring the crosstalk between gut-liver axis and oxidative stress in metabolic dysfunction-associated steatotic liver disease
by: Mi Zhou, et al.
Published: (2025-01-01)

Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Myrsini Orfanidou, et al.
Published: (2024-12-01)

Prognostic assessment of early-stage liver cirrhosis induced by HCV using an integrated model of CX3CR1-associated immune infiltration genes
by: Haozheng Cai, et al.
Published: (2025-01-01)

The clinical value of serum sirtuin-1 concentration in the diagnosis of metabolic dysfunction-associated steatotic liver disease
by: Farshad Amirkhizi, et al.
Published: (2025-01-01)

Correlation of sarcopenia with progression of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: a study from two cohorts in China and the United States
by: Fan Zhang, et al.
Published: (2025-01-01)

Establishing of a risk prediction model for metabolic dysfunction-associated steatotic liver disease: a retrospective cohort study
by: Nan Li, et al.
Published: (2025-01-01)

Nonlinear associations of the hs-CRP/HDL-C index with metabolic dysfunction-associated steatotic liver disease and advanced liver fibrosis in US adults: insights from NHANES 2017–2018
by: Bin Liang, et al.
Published: (2025-02-01)

Associations between systemic inflammatory biomarkers and metabolic dysfunction associated steatotic liver disease: a cross-sectional study of NHANES 2017–2020
by: Xin Qiu, et al.
Published: (2025-01-01)

Infection with hepatitis C virus as a cause of cirrhosis – case study
by: Lidia Sierpińska, et al.
Published: (2025-01-01)

Impact of shear wave elastography and attenuation imaging for predicting life-threatening event in patients with metabolic dysfunction-associated steatotic liver disease
by: Yudai Fujiwara, et al.
Published: (2025-02-01)

The rationale for the aggressive progression of MASLD in patients with type 2 diabetes
by: Valeria Michelle Fernández-Garibay, et al.
Published: (2025-01-01)

Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy
by: Dorota Zarębska-Michaluk, et al.
Published: (2019-01-01)

Augmenter of Liver Regeneration Crotonylation Assists in Mitochondria-ER Contact to Alleviate Hepatic SteatosisSummary
by: Xiao-lin Wang, et al.
Published: (2025-01-01)

Identification of EGR1 as a Key Diagnostic Biomarker in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Through Machine Learning and Immune Analysis
by: Wu X, et al.
Published: (2025-02-01)

Serum dihomo-g-linolenic acid concentration as a potential novel noninvasive biomarker for liver steatosis detection in children
by: Natalia Kopiczko, et al.
Published: (2024-12-01)

Association of high-sensitivity C-reactive protein with hepatic fibrosis in patients with metabolic dysfunction-associated steatotic liver disease
by: Yunfei Wu, et al.
Published: (2025-02-01)

Clinical Practice Guidelines of the Russian Society for the Study of the Liver, the Russian Gastroenterological Association, the National Scientific Society of Infectious Disease Specialists for the Diagnosis and Treatment of Chronic Hepatitis C
by: V. T. Ivashkin, et al.
Published: (2023-06-01)

The fibrosis-4 index and its association with carotid atherosclerosis in type 2 diabetes: a cross-sectional study in China
by: Ying Miao, et al.
Published: (2025-01-01)

HCV and HIV co-infection among people who inject drugs in Vietnam
by: Vu Toan THINH, et al.
Published: (2020-12-01)

Inhibition of mmu_circ_0009303 improves metabolic dysfunction-associated steatotic liver disease by regulating lipid metabolism and oxidative stress
by: Ju Zhou, et al.
Published: (2025-01-01)

Lymph Node Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Jessica M. Rubino, et al.
Published: (2025-01-01)

Non-invasive methods for diagnosing portal hypertension and variceal bleeding due to liver cirrhosis secondary to NAFLD/MASLD: systematic review
by: Nebyu Yonas Shanka, et al.
Published: (2025-01-01)

Perioperative treatment with cilostazol reverses steatosis and improves liver regeneration after major hepatectomy in a steatotic rat model
by: Sebastian Holländer, et al.
Published: (2025-01-01)

Impact of interferon-free regimens in patients with chronic HCV and successfully ablated HCC
by: Amr Maged Mahmoud Rasheed, et al.
Published: (2025-02-01)

Treatment of end-stages of liver disease in outcome of persistent hepatitis C virus infection at deficiency of donor organs
by: Ye. N. German, et al.
Published: (2011-03-01)

Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease
by: Zhifeng Gao, et al.
Published: (2025-01-01)